Oncology – Gastrointestinal
Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies
22 May, 2023 | 13:38h | UTC
Commentary on Twitter
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation:https://t.co/f4BYxY69tk #hpbcsm #medonc #camoldx #camicroenv pic.twitter.com/lqmwgp9hxh
— NatureRevClinOncol (@NatRevClinOncol) May 16, 2023
Review | Hereditary colorectal, gastric, and pancreatic cancer
18 May, 2023 | 13:43h | UTCHereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open
Commentary on Twitter
Have a🔎at our latest comprehensive review covering all u need to know📜about hereditary 🧬colorectal, gastric & pancreatic🦀! https://t.co/y1LL0DNRiy@Adductor @DrRABurkhart #SoMe4Surgery #StepUp4CRC #SurgEd #MedTwitter @BJSAcademy @BJSurgery @juliomayol @young_bjs Great read! pic.twitter.com/JmmOmMBydO
— BJS Open (@BjsOpen) May 11, 2023
Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge
16 May, 2023 | 14:52h | UTC
Commentary on Twitter
Step by step surgical roadmap 🗺️ for pancreatoduodenectomy
🧭 Pre, intra and post operative periods have specific landmarks
⚖️ Such factors weight the actual value of surgery vs. alternative options
🔑 is minimize complications and patients selectionhttps://t.co/3obsQdfHs6 pic.twitter.com/6EHoRjc2wE
— Giovanni Marchegiani (@Gio_Marchegiani) April 27, 2023
An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders
15 May, 2023 | 13:02h | UTC
2023 Rectal cancer lexicon update | Revised consensus on terminology and staging
15 May, 2023 | 12:50h | UTC
EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma
9 May, 2023 | 14:47h | UTC
Commentary on Twitter
🆕#CPG in press❕
EASL-ILCA Clinical Practice Guidelines on the management of #IntrahepaticCholangiocarcinoma
🆓Find it here👉https://t.co/buM8rgBU1F@EASLedu@EASLnews#iCCA#LiverTwitter pic.twitter.com/raR983x0qk
— Journal of Hepatology (@JHepatology) April 20, 2023
RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma
8 May, 2023 | 13:04h | UTCTislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001)https://t.co/25lyg2Ef0o pic.twitter.com/vizCPVd8bj
— The Lancet Oncology (@TheLancetOncol) April 18, 2023
RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer
5 May, 2023 | 15:13h | UTCTrifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD pic.twitter.com/gHTR9jbJS5
— NEJM (@NEJM) May 3, 2023
RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer
2 May, 2023 | 13:36h | UTCEfficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)
Commentary on Twitter
Hyperthermic intraperitoneal chemotherapy with mitomycin C along with complete cytoreduction improved locoregional control in patients with locally advanced colorectal cancer and should be considered for treatment of locally advanced colorectal cancer. https://t.co/hOM4TvgILB
— JAMA Surgery (@JAMASurgery) April 26, 2023
Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma
28 Apr, 2023 | 13:03h | UTC
M-A | Immune checkpoint inhibitors vs. chemotherapy in the 2nd-line treatment of advanced esophageal squamous cell carcinoma
28 Apr, 2023 | 12:56h | UTC
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023
Cohort Study | Circulating tumor DNA methylation may enable early detection of recurrence in colorectal cancer
24 Apr, 2023 | 13:12h | UTCEarly Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation – JAMA Oncology (free for a limited period)
Editorial: Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time? – JAMA Oncology (free for a limited period)
Commentary on Twitter
Cohort study of 299 pts w/stage I-III colorectal cancer, evaluating ctDNA evaluation w/methylation markers, showed ctDNA before & after surgery, after adjuvant chemo, & during longitudinal monitoring is highly associated w/recurrence. https://t.co/csHNz5kWz3 #CRCSM #GICSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer
19 Apr, 2023 | 13:10h | UTCPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Kelley et al – Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)https://t.co/ZbdRQwzSuW#gitwitter #onctwitter pic.twitter.com/PwoNAduQxK
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 18, 2023
RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma
17 Apr, 2023 | 13:00h | UTCZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire
Cohort Study | Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer
17 Apr, 2023 | 12:57h | UTCCancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer – The ASCO Post
Review | Diagnostic, structured classification and therapeutic approach in cystic pancreatic lesions
12 Apr, 2023 | 12:58h | UTCRelated:
Cystic pancreatic lesions: MR imaging findings and management.
Recommendations for the management of incidental pancreatic findings in adults.
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
Management of Pancreatic Cystic Lesions
Consensus Recommendations: Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions
Review: Pancreatic Cystic Lesions
Guidelines on pancreatic cystic neoplasms
Screening colonoscopy in seniors: common in patients with limited life expectancy and associated with higher complication risks
11 Apr, 2023 | 14:30h | UTCFrequency of Use and Outcomes of Colonoscopy in Individuals Older Than 75 Years – JAMA Internal Medicine (link to abstract – $ for full-text)
Related: Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy
Commentary:
In older adults >75 years of age, most screening colonoscopies were in patients in patients with limited life expectancy (defined as <10 years) and associated with increased risk of adverse events. https://t.co/XOsy2UKNRx @Jessica_Halabi @MRothbergMD @burkegastrodoc
— JAMA Internal Medicine (@JAMAInternalMed) April 4, 2023
SR | Risk factors for cholangitis after pancreatoduodenectomy
11 Apr, 2023 | 14:21h | UTC
Cohort Study | Impact of complications after resection of pancreatic cancer on disease recurrence and survival
10 Apr, 2023 | 13:34h | UTC
Commentary on Twitter
Major complications after🦀surgery are known to impair DF- and OS ➡️📜of all 🇳🇱 pat undergoing panc surgery 2014–2017 (n=1071) confirms via causal mediation 📈that this is mediated due to omission of adjuvant CTX!https://t.co/8kjr9MpRt4#some4surgery #some4hpb @BJSAcademy pic.twitter.com/EZd7Yvi4z2
— BJS Open (@BjsOpen) April 1, 2023
Brief Review | What every gastroenterologist should know about gastrointestinal neuroendocrine tumors
4 Apr, 2023 | 13:29h | UTC
Cohort Study | Celiac axis stenosis is an underestimated risk factor for increased morbidity after pancreatoduodenectomy
4 Apr, 2023 | 13:20h | UTC
Gastric Cancer: the combined impact of H. pylori infection and pathogenic gene variants
3 Apr, 2023 | 13:51h | UTCHelicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: H. Pylori Infection Negatively Modifies Genetically Increased Risk for Gastric Cancer – Physician’s Weekly
Commentary on Twitter
Infection with Helicobacter pylori is known to confer a risk of gastric cancer. In this study, persons who carried certain genetic variants and were infected with H. pylori had an excess risk of gastric cancer. https://t.co/jIcUiYu14G#genetics pic.twitter.com/jY4H1Mq6dO
— NEJM (@NEJM) March 29, 2023
Cohort Study | Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach
3 Apr, 2023 | 13:31h | UTCLong-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach – JAMA Surgery (free for a limited period)
Invited Commentary: Guiding Patients Through a “Watch-and-Wait” Approach for Rectal Cancer—Understanding the Functional Outcomes – JAMA Surgery (free for a limited period)
Related:
Commentary on Twitter
Results of this study suggest that patients with rectal cancer who were observed by a watch-and-wait approach had good quality of life, with some patients reporting bowel and sexual dysfunction. https://t.co/zaK3bjJA8n
— JAMA Surgery (@JAMASurgery) March 31, 2023